Screening for genetic abnormalities involved in ovarian carcinogenesis using retroviral expression libraries

International Journal of Oncology

Volumn 35, Issue 5, 2009, Pages 973-976

  Wada, Tomoaki ^a   Yamashita, Yoshihiro ^a   Saga, Yasushi ^a   Takahashi, Kayoko ^a   Koinuma, Koji ^a   Young, Lim Choi ^a   Kaneda, Ruri ^a   Fujiwara, Shin Ichiro ^a   Soda, Manabu ^a   Watanabe, Hideki ^a   Kurashina, Kentaro ^a   Hatanaka, Hisashi ^a   Enomoto, Munehiro ^a   Takada, Shuji ^a   Mano, Hiroyuki ^a,b   Suzuki, Mitsuaki ^a  

^a JICHI MEDICAL UNIVERSITY   (Japan)

^b JAPAN SCIENCE AND TECHNOLOGY AGENCY   (Japan)

Author keywords

NRAS; Oncogene; Ovarian cancer; Retroviral expression screening

Indexed keywords

ADENINE; CYTOKERATIN 8; CYTOSINE; GLIA MATURATION FACTOR BETA; ONCOPROTEIN; PROTEASOME SUBUNIT BETA TYPE 2; PROTEIN N RAS; RNA POLYMERASE II; UBIQUITIN SPECIFIC PROTEASE 14; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CARCINOGENESIS; CODON; CONTROLLED STUDY; DNA LIBRARY; FIBROBLAST; GENE AMPLIFICATION; GENE EXPRESSION; GENE FREQUENCY; GENE IDENTIFICATION; GENE INSERTION; GENE MUTATION; GENETIC SCREENING; MOUSE; NONHUMAN; NUCLEIC ACID BASE SUBSTITUTION; OVARY CANCER; PRIORITY JOURNAL;

AMINO ACID SEQUENCE; ANIMALS; BASE SEQUENCE; CELL LINE, TUMOR; FEMALE; GENE LIBRARY; GENES, RAS; GENETIC TESTING; HUMANS; MICE; MOLECULAR SEQUENCE DATA; OVARIAN NEOPLASMS; RETROVIRIDAE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 70449563097     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo_00000410     Document Type: Article

References (25)

1. Jemal A, Siegel R and Ward E: Cancer statistics, 2008. CA Cancer J Clin 58: 71-76, 2008.
2. Armstrong DK, Bundy B and Wenzel L: Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med 354: 34-43, 2006. (Pubitemid 43048949)
3. Druker BJ, Talpaz M and Resta DJ: Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 344: 1031-1037, 2001. (Pubitemid 32267972)
4. Maloney DG, Grillo-Lopez AJ and White CA: IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. Blood 90: 2188-2195, 1997. (Pubitemid 27392702)
5. Okamoto A, Sameshima Y and Yokoyama S: Frequent allelic losses and mutations of the p53 gene in human ovarian cancer. Cancer Res 51: 5171-5176, 1991.
6. Esteller M, Silva JM and Dominguez G: Promoter hypermethylation and BRCA1 inactivation in sporadic breast and ovarian tumors. J Natl Cancer Inst 92: 564-569, 2000. (Pubitemid 30212318)
7. Soda M, Choi YL and Enomoto M: Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 448: 545-546, 2007. (Pubitemid 47206930)
8. Imai S, Kiyozuka Y and Maeda H: Establishment and characterization of a human ovarian serous cystadenocarcinoma cell line that produces the tumor markers CA-125 and tissue polypeptide antigen. Oncology 47: 177-184, 1990. (Pubitemid 20075560)
9. Yoshizawa H, Adashi S and Misawa Y: Isolation of cisplatin-resistant subline from human ovarian cancer cell line and analysis of its cell-biological characteristics (in Japanese). Nihon Sanfujinka Gakkai-shi 141: 7-14, 1989.
10. Pear WS, Nolan GP and Scott ML: Production of high-titer helper-free retroviruses by transient transfection. Proc Natl Acad Sci USA 90: 8392-8396, 1993. (Pubitemid 23277674)
11. Onishi M, Kinoshita S and Morikawa Y: Applications of retrovirus-mediated expression cloning. Exp Hematol 24: 324-329, 1996.
12. Kent WJ: BLAT - the BLAST-like alignment tool. Genome Res 12: 656-664, 2002.
13. Aaronson SA: Growth factors and cancer. Science 254: 1146-1153, 1991.
14. Kisanuki H, Choi YL and Wada T: Retroviral expression screening of oncogenes in pancreatic ductal carcinoma. Eur J Cancer 41: 2170-2175, 2005. (Pubitemid 41337960)
15. Choi YL, Moriuchi R and Osawa M: Retroviral expression screening of oncogenes in natural killer cell leukemia. Leuk Res 29: 943-949, 2005. (Pubitemid 40840722)
16. Shih TY and Weeks MO: Oncogenes and cancer: the p21 ras genes. Cancer Invest 2: 109-123, 1984.
17. Nikiforova MN, Lynch RA and Biddinger PW: RAS point mutations and PAX8-PPAR gamma rearrangement in thyroid tumors: evidence for distinct molecular pathways in thyroid follicular carcinoma. J Clin Endocrinol Metab 88: 2318-2326, 2003.
18. Taparowsky E, Shimizu K and Goldfarb M: Structure and activation of the human N-ras gene. Cell 34: 581-586, 1983.
19. Ichikawa Y, Nishida M and Suzuki H: Suppression of metastasis of rat prostatic cancer by introducing human chromosome 8. Cancer Res 54: 2299-2302, 1994. (Pubitemid 24138712)
20. Suzuki M, Saito S and Saga Y: Mutation of K-RAS protooncogene and loss of heterozygosity on 6q27 in serous and mucinous ovarian carcinomas. Cancer Genet Cytogenet 118: 132-135, 2000. (Pubitemid 30169214)
21. Shih IeM and Kurman RJ: Molecular pathogenesis of ovarian borderline tumors: new insights and old challenges. Clin Cancer Res 11: 7273-7279, 2005.
22. Mammas IN, Zafiropoulos A and Spandidos DA: Involvement of the ras genes in female genital tract cancer (review). Int J Oncol 26: 1241-1255, 2005.
23. Zhang X, Vincent P and McHugh M: BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/ MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 64: 7099-7109, 2004. (Pubitemid 39331023)
24. Wilhelm SM, Carter C and Tang L: Proteasome inhibition and its clinical prospects in the treatment of hematologic and solid malignancies. Cancer 104: 1794 - 1807, 2005.
25. Hendrix MJC, Seftor EA and Chu YW: Role of intermediate filaments in migration, invasion and metastasis. Cancer Metastasis Rev 15: 507-525, 1996. (Pubitemid 27067169)